Dr. Lal PathLabs Limited

NSE LALPATHLAB.NS

Dr. Lal PathLabs Limited EBIT for the year ending March 31, 2024: USD 64.12 M

Dr. Lal PathLabs Limited EBIT is USD 64.12 M for the year ending March 31, 2024, a 38.19% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Dr. Lal PathLabs Limited EBIT for the year ending March 31, 2023 was USD 46.40 M, a -30.26% change year over year.
Dr. Lal PathLabs Limited EBIT for the year ending March 31, 2022 was USD 66.53 M, a 18.70% change year over year.
Dr. Lal PathLabs Limited EBIT for the year ending March 31, 2021 was USD 56.05 M, a 29.64% change year over year.
Dr. Lal PathLabs Limited EBIT for the year ending March 31, 2020 was USD 43.23 M, a -0.03% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NSE: LALPATHLAB.NS

Dr. Lal PathLabs Limited

CEO	Mr. Shankha Banerjee
IPO Date	Dec. 23, 2015
Location	India
Headquarters	Tower B, SAS Tower
Employees	4,099
Sector	Health Care
Industries Biotechnology Hospitals & Clinics Medical Instruments Pharmaceuticals

Description

Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company also offers lab staff training; technical; and lab management services. As of March 31, 2022, the company had 277 clinical laboratories, including National Reference Lab at Delhi and Regional Reference Lab at Kolkata; and 4,731 patient service centers and 10,599 pick-up points. Dr. Lal PathLabs Limited was founded in 1949 and is based in Gurugram, India.

Key trends

Past 5 years